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Abstract. Background/Aim: Epithelioid haemangioendo-
thelioma (EHE) is a rare tumor with a wide spectrum of
clinical behavior. There is no consensus on the role of local
therapy in symptomatic, multi-focal disease. Patients and
Methods: A retrospective review of patients presenting to the
Royal Marsden Hospital between January 2000 and December
2017 was conducted. Results: Fifty-three patients with EHE
were identified, of which 18 patients (34.0%) received local
therapy, and 11 patients (20.8%) underwent active
surveillance. A variety of local treatment modalities were used
with few toxicities, and local recurrence was managed with
other local treatments or systemic therapy. Distal disease
progression was infrequent (n=4, 7.5%). Patients who
developed pleural effusion (n=5, 9.4%) had poor outcome
irrespective of treatment. Conclusion: Local therapy has a role
in a selected patient group managed in a multidisciplinary
setting, including patients with indolent disease, and patients
with a solitary area of progression/symptomatic disease.  
Epithelioid haemangioendothelioma (EHE) is a rare vascular
tumor originating from endothelial cells (1) with an
incidence of one in a million (2). It was first described in
1975 and later termed EHE in 1982 by Weiss and Enzinger
(3). It is characterized by the translocation of chromosome 1
and 3 and as a result the fusion of WW domain-containing
transcription regulator 1 (WWTR1) and calmodulin-binding
transcription activator 1 (CAMTA1) (4).  It often presents as
a multi-focal disease, and can originate in different sites,
commonly in the liver and lung. EHE has a wide spectrum
of clinical behavior, and can follow an indolent course but
can also be very aggressive (1). 
Due to its rarity, there are few published data regarding the
management of this disease and there is no consensus
regarding the optimal management of multi-focal disease. For
patients with an indolent disease pattern, active surveillance is
considered optimal management. However, there is very little
information regarding the safety and efficacy of local therapy
in symptomatic or solitary progressive disease. The available
literature is limited to case reports documenting the use of a
single modality. Therefore, the aim of this study was to analyze
the safety and efficacy of local therapy in multi-focal EHE in
a series of patients treated at a single referral center. 
Patients and Methods
Local institutional approval was obtained to perform the study. A
retrospective search of the prospectively maintained Royal Marsden
Sarcoma Unit database was performed to identify EHE patients
treated at the Royal Marsden Hospital between January 2000 and
December 2017.
The diagnosis of EHE was confirmed in all cases by an
experienced soft tissue sarcoma pathologist (KT, CF). Patient
demographics, date of diagnosis, disease location, treatment, follow-
up and survival data were obtained from the database and electronic
patient record. Patients only seen at the Royal Marsden for a second
opinion were not included in this analysis.
Local treatments included were primary resection, re-excision,
metastasectomy, radiofrequency ablation (RFA), irreversible
electroporation (IRE), liver transplant and radiotherapy (RT).
Systemic treatments included chemotherapy, non-steroidal anti-
inflammatory drug administration such as celecoxib, mTOR
inhibition or enrolment in a Phase I trial. 
Patients on active surveillance underwent repeat imaging every
3-6 months, with either computed tomography (CT) or magnetic
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resonance imaging (MRI). For patients treated with local therapy,
response was evaluated 2-3 months following the procedure.
Toxicity data were obtained from the electronic patient record.
Descriptive statistics were used. Progression-free survival (PFS)
was defined as time between treatment initiation and disease
progression. Local disease progression was defined as progression
of tumor sites present at staging, and distant progression was
progression of distal sites not involved at the time of diagnosis.
Overall survival (OS) was defined as time from diagnosis to date of
death. Outcomes were presented as median PFS and OS. 
Results
Sixty-two patients with EHE presented to the Royal Marsden
Hospital between 2000 and 2017 (Figure 1). Nine patients
were excluded from the analysis due to follow-up in local
hospitals. Twenty-nine of these patients received local
treatments or active surveillance at the Royal Marsden
Hospital, while 24 had systemic therapy. The outcomes in
this group are reported in a separate publication (5). The
median age was 41.5 years (range=16-72) in the local
treatment group and 51 years (range=29-76) in those under
surveillance (Table I). Liver and lung were the most common
sites involved. Patient demographics and tumor
characteristics at diagnosis are summarized in Table I.
Eighteen patients (34.0%) received local treatments for
EHE, and 11 patients (20.7%) had active surveillance (Figure
1). Nine (50%) of the patients in the local treatment group
had multi-focal disease at diagnosis, and all 11 patients in the
surveillance group had multi-focal disease (Table I). Two
patients in the surveillance group proceeded to have local
therapy on disease progression. Primary resection was used
in 10 patients, while other first-line treatment modalities in
the local treatment group included radiotherapy (n=6),
radiofrequency ablation (n=1), endovascular embolization
(n=1), liver transplant (n=1) (Table II). Further lines of local
treatments used were metastasectomy (n=1), irreversible
electroporation (n=1), and re-excision (n=2, with one patient
undergoing two further re-excisions following primary
surgery). Details of treatment and outcome can be found in
Table III. 
Surgery +/– other local treatment (n=10). Two (20%)
patients in this group had multi-focal disease at the time of
diagnosis. Ten patients had primary resection for EHE, and
six did not require further treatment after a median follow-up
of 27.5 months. Two patients needed further re-excision of
the primary site. The first patient had residual disease excised
and was found to have positive regional lymph nodes which
were unresectable. The patient then underwent active
surveillance, and is well 25 months following the re-excision
with no recurrence at the primary site and stable appearance
of the nodal disease. The second patient, who had multifocal
disease at the time of first surgery, had two further re-
excisions of the primary sites following local disease
progression at 4 months and 18 months, respectively, from
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Table I. Patient demographics and tumor characteristics.
                                                               Local treatment     Surveillance
Number of patients                                          18                        11
Median age                                                       41.5                     51
Gender                                                                                               
  Male                                                                 5                          1
  Female                                                            13                        10
Multi-focal disease at diagnosis                          
  Yes                                                                    9                         11
  No                                                                     9                          0
Sites involved at diagnosis                                                              
  Liver                                                                 7                          7
  Lung                                                                 6                        10
  Bone                                                                 4                          2
  Bowel                                                              1                          0
  Vulva                                                                2                          0
  Limbs                                                               3                          0
  Peritoneal                                                         2                          0
  Mediastinum                                                    1                          1
  Groin                                                                1                          0
  Spine                                                                2                          0
  Lymph node                                                     1                          0
Table II. Local treatments given for EHE at RMH.
Local treatment modality                                           n (%)
Surgery                                                                   10 (34.5)
Surgical re-excision                                                 2 (6.9)
Metastasectomy                                                        1 (3.4)
Liver transplant                                                        1 (3.4)
Radiotherapy (including protons)                           6 (15.4)
Radiofrequency ablation                                          1 (3.4)
Irreversible electroporation                                     1 (3.4)
Endovascular embolization                                     1 (3.4)
Figure 1. Treatment received by all EHE patients presented to RMH in
the period covered by this study.
the first operation, ultimately resulting in an above-knee
amputation. The disease is stable in the lung and liver 6
months following the above knee amputation. 
Of the 10 primarily surgically managed patients, eight
(80%) were free of local recurrence with a median follow-up
of 31 months (range=2-56). Local recurrence was found in
two patients (20%), with a median PFS of 9.5 months. One
patient was treated with surgical re-excision as described
above and the other with irreversible electroporation (IRE).
The other patient had multi-focal disease in the lung and liver
and was treated with IRE to the enlarging liver tumors 15
months after primary resection. IRE was performed in two
metastases measuring 5.4 cm and 3.2 cm. The patient is
progression-free 9 months following the procedure. Patient
No. 2 in Table III had residual disease excised upon review of
post-operative pathology and was therefore not deemed to
have local recurrence. This patient had residual disease
excised and is free of recurrence at the 35-month follow-up.
Nine (90%) patients had no evidence of distant recurrence
with a median follow-up of 24 months. One patient
developed distant recurrence in the liver and underwent
metastasectomy 7 months following primary surgery. He is
now recurrence-free, 23 months after the procedure. 
All 10 patients were alive at the time of analysis, with a
median follow-up of 27 months. 
In terms of toxicity, one patient developed a seroma post-
operatively which was drained, and another patient developed
post-operative chronic pain following primary resection of an
upper limb EHE requiring ongoing input from the pain team. 
Other local treatments without primary surgery (n=8). All
patients had multi-focal disease at diagnosis. One patient had
liver transplantation, six had radiotherapy, one had
endovascular embolization followed by proton therapy, and
one had radiofrequency ablation. Five patients developed
local recurrence (median local PFS= 8 months), and two
patients received systemic treatment, two underwent
surveillance, and one had surgical excision. Three (37.5%)
patients remained disease-free at 21 months median follow-
up. Two patients had distal progression (median distal
PFS=10.5 months), one was started on systemic treatment
and the other on surveillance. Six (75%) remained disease-
free at 37 months median follow-up. Four (50%) patients
were alive at the time of analysis (median follow-up= 44.5
months), four had died at the time of analysis and had a
median OS of 36.5 months. No significant adverse events
were recorded. 
One patient had multi-focal disease in the liver and
underwent liver transplant one year following diagnosis. She
subsequently developed multi-focal liver lesions 31 months
post-transplant which slowly increased in size. She eventually
had a partial hepatectomy after 18 months of surveillance due
to an increase in the size of the lesions, and is recurrence-free
at 11 months post-op (72 months follow-up). 
One patient underwent endovascular embolization 10
months following diagnosis. The patient then received proton
therapy two months following endovascular embolization
(<18 years old at diagnosis). The patient developed
metastasis one month following completion of proton
therapy and received chemotherapy (doxorubicin/ ifosfamide
for three cycles, followed by paclitaxel on progression). She
passed away five months after starting chemotherapy
(OS=21 months).  
A patient with disease in the liver, lung, retroperitoneum
and bone was treated with RFA to a liver lesion (6 months
from diagnosis). There was evidence of local progression in
the liver 7 months following RFA. She was started on
celecoxib and died 2 months later (OS=15 months). 
The two patients described above both developed pleural
effusion and the time from event to death was 6 and 2
months respectively. 
Radiotherapy was given to six patients for bone
metastases. Two received radical treatment one of which was
delivered via stereotactic ablative technique and one had
proton therapy (outcome described above). The patient with
stereotactic ablative radiotherapy had a local PFS of 62
months and on recurrence was given chemotherapy. The
patient has stable disease at 11 months follow-up. Among the
four patients receiving conventional RT, whilst one did not
develop further disease-events (median follow-up 52
months), two patients developed local recurrence (PFS 8 and
9 months respectively) and one developed distant
progression at 20 months. These were all managed with
active surveillance.
Surveillance group (n=11). Eleven patients with multi-
focal disease at the time of diagnosis were treated
conservatively with active surveillance. Six patients had
progression in primary disease sites with a median PFS of
29 months. Of these six, two patients continued on
surveillance, one was referred for liver transplant and one
for IRE. Two were started on chemotherapy. Three patients
in the surveillance group developed pleural effusion. In the
surveillance group, there was no progression in five
(45.4%) patients (median follow-up 29 months), and no
distal progression in any patient. Six (54.5%) patients were
alive at the time of analysis (median follow-up 35
months). Five had died at the time of analysis (median
OS=29 months), and two of the five deaths were unrelated
to malignancy. 
Pleural effusion appeared to be a poor prognostic factor in
EHE. Among patients treated with local therapy or
surveillance, it was present in five (9.4%) patients. Three
patients had systemic treatment and two were treated
conservatively. All five patients had died at time of analysis
with a median time from development of pleural effusion to
death of five months. 
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Discussion 
EHE is a rare disease with a wide spectrum of clinical
behavior ranging from very indolent to an extremely
aggressive life-threatening disease. There are limited published
data regarding the use of local therapy in multi-focal EHE.
Our study suggests that local therapy may have a role even in
patients with multi-focal disease in selected patients managed
within a multidisciplinary team. Our study is of course limited
by its retrospective nature and relatively small patient
population. However, it does provide a benchmark for the use
of local therapy in multi-focal EHE. Due to the often-indolent
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Table III. Local treatment modalities and their respective outcomes.
Patient           Disease                 Multi-focal               Treatment               Interval between        Local PFS       Distal PFS                  Toxicity
no.                     sites                    at diagnosis                 modality               treatment (months)        (months)           (months)
Local treatment surgery
1                  Lower limb                     No                         Surgery                              0                       Nil at 56          Nil at 56                        Nil
2                       Vulva                          No             Surgery & re-excision                 0                       Nil at 35           Nil at 35                        Nil
                                                                                 of residual disease
3                   Upper limb                     No                         Surgery                              0                       Nil at 32           Nil at 32          Post-op chronic pain
4                       Vulva                          No                         Surgery                              0                       Nil at 37           Nil at 37                        Nil
5                  Bowel, liver                    No                         Surgery                              0                       Nil at 30                 7                               Nil
                                                                                   Metastasectomy                       7                       Nil at 23           Nil at 23                        Nil
6                    Peritoneal                      No                         Surgery                              0                       Nil at 23           Nil at 23                        Nil
7                   Liver, lung                     Yes                        Surgery                              7                            15                Nil at 24                        Nil
                                                                                             IRE                                15                       Nil at 9            Nil at 9                         Nil
8         Lower limb, lung, liver           Yes                        Surgery                              0                             4                 Nil at 24                        Nil
                                                                                      Re-excision                           4                            14                Nil at 24                        Nil
                                                                                      Re-excision                          14                       Nil at 6            Nil at 24                        Nil
9                       Groin                          No                         Surgery                            240                      Nil at 3             Nil at 3                      Seroma
10                      Liver                          No                         Surgery                              0                        Nil at 2             Nil at 2                          Nil
Local treatment without surgery
11               Scapula, liver                   Yes                    Radiotherapy                         4                       Nil at 29                20                              Nil
12                      Liver                          Yes                  Liver transplant                      12                            7                 Nil at 60                        Nil
                                                                                          Surgery                             49                      Nil at 11           Nil at 11                         Nil
13                 Bone, lung                     Yes                    Radiotherapy                         2                             9                 Nil at 12                        Nil
14               Mediastinum                   Yes              Radiotherapy (SRS)                   11                           62                Nil at 73                        Nil
15        Spine, bone, lung, LN            Yes                    Radiotherapy                        37                      Nil at 15           Nil at 15                        Nil
16                 Bone, lung                     Yes                    Radiotherapy                        49                            8                 Nil at 59                        Nil
17                     Spine                         Yes        Endovascular embolization              3                       Nil at 21                 5                               Nil
                                                                                    Proton therapy                        5                       Nil at 21                 1                               Nil
18           Liver, bone, lung,               Yes                           RFA                                 6                             7                 Nil at 15                        Nil
                retroperitoneum                   
Patient no.              Disease sites                Multi-focal at diagnosis               Treatment modality                Local PFS (months)      Distal PFS (months)
Surveillance
19                             Liver, lung                                  Yes                                     Surveillance                               Nil at 26                        Nil at 26
20                             Liver, lung                                  Yes                                     Surveillance                              Nil at 106                      Nil at 106
21                             Liver, lung                                  Yes                                     Surveillance                              Nil at 158                      Nil at 158
22                                  Liver                                       Yes                          Surveillance (referred for                         49                              Nil at 51
                                                                                                                             liver transplant)
23                             Liver, lung                                  Yes                      Surveillance (referred for IRE)                     36                              Nil at 36
24                             Lung, bone                                  Yes                                     Surveillance                                     3                               Nil at 24
25                             Liver, lung                                  Yes                                     Surveillance                                    39                              Nil at 46
26                                  Lung                                       Yes                                     Surveillance                                     2                               Nil at 73
27                             Liver, lung                                  Yes                                     Surveillance                                    22                              Nil at 34
28                       Lung, mediastinum                           Yes                                     Surveillance                               Nil at 29                        Nil at 29
29                             Lung, bone                                  Yes                                     Surveillance                                Nil at 2                          Nil at 2
nature of the disease, resection of symptomatic/ progressing
lesions could be considered. The pros and cons of this
approach should be considered with each individual patient.
In our series, 80% of our patients having upfront primary
resection did not have multi-focal disease at the time of
diagnosis. Our experience is that surgical excision improves
local PFS compared to active surveillance when disease
burden is assessed, but distal PFS is similar. 
A number of retrospective studies have reported the
outcome of EHE patients treated with liver transplantation
(LT) (6-8). These studies are limited by an inherent selection
bias and their retrospective nature. Given that many patients
with multi-focal EHE have indolent disease and are on active
surveillance, it is difficult to define precisely the role of liver
transplantation in this disease, i.e. patients treated with
transplantation may have indolent disease and it is possible
that they would have a good outcome without
transplantation. Bonaccorsi-Riani et al. suggested that EHE
patients receiving LT have a 5-year overall survival of 83%
and progression-free survival of 82%, based on the results
from the European Liver Intestinal Transplant Association,
European Liver Transplant Registry (ELTR) (6-7). However,
it is unclear whether LT influenced outcome in these
patients, as EHE can often be very indolent. Grotz et al.
conducted a retrospective review of 30 patients treated in a
single center. Five-year OS was worse (p<0.05) in those
presenting with liver-only disease with diffuse disease
pattern (disease involving >4 lobes, >10 tumor nodules,
tumor size >10 cm) (8). LT was recommended in those
presenting with these risk factors. Lai et al. analyzed data
from the ELTR and proposed a risk score (HEHE-LT) to
stratify patients to identify those who would benefit from LT
according to risk of recurrence after transplantation (9). The
risk factors associated with recurrence that were identified
include pathological invasion of hilar lymph nodes and
macrovasculature, and, interestingly, a short waiting time to
transplantation (<120 days). This suggests that an assessment
of the pace of disease progression is crucial before planning
extensive surgical procedures.
Radiotherapy (RT) is normally used in EHE as an adjunct
to other treatments such as chemotherapy. Current literature
on the role for radiotherapy in EHE are mostly described in
single case reports. For example, Albakr et al. described a
34-year-old with thoracic spinal EHE treated with adjuvant
radiotherapy following surgical decompression for an
epidural tumor causing cord compression (10). Similarly,
Guy et al. published a case of a vertebral EHE receiving
volumetric intensity-modulated radiotherapy following
failure of surgery (11). A number of case series have
investigated the role of RT in EHE with bone involvement.
Wold et al. presented 38 patients with bony EHE treated with
RT (12). In 21 patients RT was used as monotherapy, 8 in
adjuvant setting, and 9 combined with chemotherapy. 48%
of these achieved local control, and 93% of these were in the
group with the higher radiotherapy dose (>50 Gy). At
median follow-up of 2.9 years, OS was 75% in the higher-
dose group and 40% for those who received a lower dose.
Yim et al. suggested that RT may be used in cases where
radical resection is not possible, although the evidence of
this is not clear (13). 
There are limited data regarding radiation in this disease,
but it can be used for palliation of symptomatic lesions. 
Radiofrequency ablation (RFA) is commonly used to treat
hepatic lesions. The use of RFA in bony EHE has been
described in case reports. Davis et al. treated multi-focal
EHE with bony lesions with wide excision of soft tissue
lesions and RFA to bony lesions (14). Rosenthal et al.
reported the use of RFA when primary resection alone would
result in significant co-morbidity due to the location of tumor
(15). RFA was recommended as an adjunct to limit the extent
of surgery, particularly when it would result in significant
cosmetic or functional deficit.
Irreversible electroporation (IRE) is a non-thermal focal
ablation technique and its use in hepatic EHE has been
described in a case report, documenting significant reduction
in FDG-PET uptake following IRE (16). IRE was used in
this particular case because RFA was contraindicated due to
the vasculocentric nature of the target lesions. RFA in such
lesions with low vascularity would likely not sustain a
therapeutic response (16). IRE is a therapeutic modality
warranting further exploration in EHE.
In summary, EHE is a rare condition, and is best managed
at referral centers with a multidisciplinary approach. Local
therapy can be considered for patients with indolent disease,
including those with indolent multifocal disease with a solitary
area of progression/symptomatic lesion. Pleural effusion is a
poor prognostic marker in EHE, and early involvement of the
palliative care team is particularly important in this group. 
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